Pathos Communications reported first-half 2026 revenue of $7.3 million, up 14% year over year, while adjusted EBITDA ...
Contrary Games is thrilled to announce that Pathos will arrive on PC via Steam on 4 November, with a demo coming out in a few ...
Pathos AI, a startup that developed artificial intelligence-enabled technologies for cancer drug research, has secured rights to two molecules whose clinical testing will proceed with a proprietary ...
In a single news cycle, Pathos AI announced two simultaneous drug licensing agreements worth up to $2.3 billion in combined milestones — and disclosed that it is targeting a $300 million Series E ...
While teaching a class on intelligence and analysis last year, I asked my graduate students why the media’s shocking picture of the drowned Syrian boy seemed to have such an incredible effect on ...
Pathos AI has secured $365 million in a series D raise as the artificial-intelligence-powered biotech looks to fund trials of solid tumor drugs sourced from Novo Nordisk and Prelude Therapeutics. The ...
Pathos AI Enters Collaboration and Co-Exclusive Licensing Agreement to Advance Novel ERα PROTAC for ER+ Breast Cancer into the Clinic Pathos assumes responsibility for early clinical development of ...
Iker Huerga, Pathos AI's chief executive. Pathos AI has added to its pipeline of cancer drugs by licensing a bispecific antibody-drug conjugate (ADC) for solid tumours from China's Alphamab in a deal ...
AstraZeneca has started work with tech companies Tempus and Pathos AI on a project that aims to generate a wide-ranging and comprehensive generative artificial intelligence model for oncology. The ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results